LifeCycle Pharma Receives Special Protocol Assessment (SPA) from FDA for LCP-Tacro™ Pivotal Phase 3 Study in De Novo Kidney Transplant Patients

LifeCycle Pharma's pivotal Phase 3 3002 Study for LCP-TacroTM will be initiated in 2010.

Hørsholm, Denmark, August 12, 2010:

LifeCycle Pharma A/S (OMX: LCP) today announced receipt of agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) of its pivotal Phase 3 study, Study 3002, for LCP-Tacro^TM in patients, who have just received a kidney transplant ("de novo" transplant patients).

Click here to read LCP's news release.